Ex-Pfizer facility has successful pre-approval inspection

CMO Pillar5, selected by IntelGenx to manufacture its high-strength CPI-300 bupropion hydrochloride antidepressant, has passed its FDA pre-approval inspection with no Form 483 being issued. The agency visited Pillar5's Arnprior, Ontario manufacturing facility, a former Pfizer plant that dates from 1956. Pillar5 moved in in 2009 and employs about 100. IntelGenx release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)